$152.16
-4.45-2.84%
Last update: Nov 10, 3:56 PM
Alnylam Pharmaceuticals Inc
ALNYNASDAQ
Alnylam Pharmaceuticals fell 64.5% from $441.70 to $156.61, behind the S&P 500's +10.5%. Its worst day was Jul 30 (−28.3%), and its low came Nov 6 at $155.94.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Alnylam Pharmaceuticals closed at its highest level of the year, 7.2% above where the year started.
+4.9% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $1.25 beat the $1.20 estimate on $1.1B revenue (est. $1.2B); FY revenue guidance of $5.3B–$5.8B against the $5.5B consensus.
−4.3% · S&P 500 −1.5%
EPS of $1.99 beat the $1.36 estimate on $1.2B revenue (est. $1.1B); FY revenue guidance of $5.3B–$5.8B against the $5.6B consensus.
+2.8% · S&P 500 +1.0%
EPS of $1.84 missed the $2.00 estimate on $1.3B revenue (est. $1.3B); FY revenue guidance of $5.3B–$5.7B against the $5.6B consensus.
−28.3%, the year's worst day · S&P 500 +1.7%
Alnylam Pharmaceuticals shares rose 8.7%, while the S&P 500 rose 0.4%.
+8.7%, the year's best day · S&P 500 +0.4%
EPS of $16.26 beat the $2.09 estimate on $1.5B revenue (est. $1.4B); FY revenue guidance of $5.3B–$5.7B against the $5.5B consensus.
−25.1% · S&P 500 −0.4%
Where it ended: a close of $156.61 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $2.20, revenue est. $1.5B).
Nothing in the past 12 months.
All ALNY dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALNY and SPY from Benzinga historical bars. Not investment advice.
